{"id":567851,"date":"2026-02-05T10:24:15","date_gmt":"2026-02-05T10:24:15","guid":{"rendered":"https:\/\/www.europesays.com\/us\/567851\/"},"modified":"2026-02-05T10:24:15","modified_gmt":"2026-02-05T10:24:15","slug":"innovative-car-t-therapy-destroys-cancer-cells-without-dangerous-side-effects","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/567851\/","title":{"rendered":"Innovative CAR-T therapy destroys cancer cells without dangerous side effects"},"content":{"rendered":"<p> <img decoding=\"async\" class=\"figure__image\" alt=\"Engineered T-cell (pink) upon a prostate cancer cell.\" loading=\"lazy\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/02\/d41586-026-00358-6_52019400.jpg\"\/><\/p>\n<p class=\"figure__caption u-sans-serif\">Engineered T cells (pink) produce proteins called chimeric antigen receptors that target antigens in cancer cells (blue).Credit: Steve Gschmeissner\/Science Photo Library<\/p>\n<p>A new generation of engineered immune cell destroys cancer cells in mice<a href=\"#ref-CR1\" data-track=\"click\" data-action=\"anchor-link\" data-track-label=\"go to reference\" data-track-category=\"references\">1<\/a> as effectively as conventional CAR-T-cell therapies without suppressing the immune system, a serious side effect. The engineered cells could also be used to treat some people with autoimmune conditions, such as lupus.<\/p>\n<p>CAR-T-cell therapy involves tweaking a person\u2019s immune cells known as T cells to produce proteins called chimeric antigen receptors (CARs). These receptors target antigens on B cells, another type of immune cell, in tumours. Conventionally, this antigen of choice has been the CD19 molecule.<\/p>\n<p>Researchers have developed a CAR-T-cell therapy called CART4-34 that targets B cell receptors carrying the gene IGHV4-34 \u2014 thought to be involved in immune responses \u2014 which is found in high levels in cancer cells. The scientists found that CART4-34 therapy was as effective as CD19 CAR-T therapy at destroying cancer cells in genetically modified mice with a cancer called diffuse large B cell lymphoma. The CART4-34 therapy did not target healthy, non-cancerous B cells. The IGHV4-34 gene is rarely found in healthy cells.<\/p>\n<p>CD19 CAR-T therapy, however, destroys any cells carrying the CD19 molecule, which leads to the suppression of the immune system, says Andrea Henden, a clinician\u2013researcher at the QIMR Berghofer Medical Research Institute in Brisbane, Australia. \u201cIf you\u2019re lucky enough to get a cure for your lymphoma, the most likely other threat to your health is through infection,\u201d she adds. \u201cIt is quite a fundamental problem with our current use of CAR T cells.\u201d<\/p>\n<p>Autoimmune diseases<\/p>\n<p>The engineered T cells could also treat some autoimmune conditions. Antibodies that target cells carrying IGHV4-34 are present in many people with lupus and are associated with more aggressive forms of the disease, says Marco Ruella, a clinician\u2013researcher at the University of Pennsylvania in Philadelphia, whose team developed the CART4-34 therapy.<\/p>\n","protected":false},"excerpt":{"rendered":"Engineered T cells (pink) produce proteins called chimeric antigen receptors that target antigens in cancer cells (blue).Credit: Steve&hellip;\n","protected":false},"author":3,"featured_media":567852,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[8],"tags":[235,884,10046,3740,10047,159,67,132,68],"class_list":["post-567851","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science","tag-cancer","tag-diseases","tag-humanities-and-social-sciences","tag-medical-research","tag-multidisciplinary","tag-science","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116017540037390370","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/567851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=567851"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/567851\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/567852"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=567851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=567851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=567851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}